19-383 - A Study of Suboptimally Controlled Participants Previously Taking Oral Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)
Status: openCladribine tablets: Observational evaluation of effectiveness and patient-reported outcomes (PROs) in suboptiMAlly controlled patientS previously Taking oral disEase-modifying dRugs (DMDs) for relapsing forms of multiple sclerosis (RMS) (MASTER-2)
Patients with relapsing Multiple Sclerosis (RMS)
Contact Us
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by phone at +1 (251) 665-8375 or by email at dlwilliams@health.southalabama.edu.
Description
The purpose of this study is to evaluate the effectiveness and safety of cladribine tablets in participants with relapsing form of multiple sclerosis (RMS) including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS) who transition to cladribine tablets after suboptimal response to any oral DMD approved in the United States for RMS in a real-world setting.
